Researchers identify new approach to overcome resistance to KRAS-targeted therapies
Many cancers with KRAS mutations, the most commonly mutated oncogene, develop rapid resistance to targeted therapy with KRAS inhibitors. A recent study by Wantong Yao, M.D., Ph.D., Scott Kopetz, M.D., Ph.D., and Haoqiang Ying, M.D. Ph.D., and colleagues discovered that SDC1, a cell surface protein involved downstream of the KRAS-mutated pathway and associated with pancreatic cancer progression, plays a critical role in acquired resistance...
Machine learning model improves treatment selection in non-small cell lung cancer
A significant challenge in developing treatment plans for patients with metastatic non-small cell lung cancer (NSCLC) is deciding whether...